[null, {"document_url": "http://blog.gnshealthcare.com/topic/drug-development", "unformatted_src": "https://blog.gnshealthcare.com/hubfs/iStock-538406951-1.jpg", "src": "https://blog.gnshealthcare.com/hubfs/iStock-538406951-1.jpg", "formatted_filename": "iStock", "alt_text": "iStock-538406951-1"}, null, {"document_url": "http://blog.gnshealthcare.com/topic/drug-development", "unformatted_src": "https://blog.gnshealthcare.com/hubfs/iStock-669121480.jpg", "src": "https://blog.gnshealthcare.com/hubfs/iStock-669121480.jpg", "formatted_filename": "iStock", "alt_text": "iStock-669121480"}, null, {"document_url": "http://blog.gnshealthcare.com/topic/drug-development", "unformatted_src": "https://blog.gnshealthcare.com/hubfs/gns-image-for-blog%20%28002%29.png", "src": "https://blog.gnshealthcare.com/hubfs/gns-image-for-blog%20%28002%29.png", "formatted_filename": "gns image for blog", "alt_text": "gns-image-for-blog (002)"}, null, {"document_url": "http://blog.gnshealthcare.com/topic/drug-development", "unformatted_src": "https://blog.gnshealthcare.com/hubfs/DNA%20Humans.jpg", "src": "https://blog.gnshealthcare.com/hubfs/DNA%20Humans.jpg", "formatted_filename": "DNA Humans", "alt_text": "DNA Humans"}, null, {"document_url": "http://blog.gnshealthcare.com/topic/drug-development", "unformatted_src": "https://blog.gnshealthcare.com/hubfs/GNS_Healthcare_October2018%20Theme/Images/HiTrust-Certified.jpg", "src": "https://blog.gnshealthcare.com/hubfs/GNS_Healthcare_October2018%20Theme/Images/HiTrust-Certified.jpg", "formatted_filename": "HiTrust Certified", "alt_text": "HITRUST"}, null]
GNS Healthcare Blog


GNS Healthcare Primary Blog

By December 31, 1969 Are value-based contracts the end of the journey or just a stop along the way?

By GNS Healthcare | Real World Evidence, Value Based Care, Drug Discovery, Drug Development

The drive to value-based care has become a significant issue for biopharma companies as more health plans request value-based contracts. According to McKinsey, over 200 of these innovative contracts have been publicly disclosed since 1994¹. The buzz around the biopharma industry is that these value-based contracts are the wave of the future. Although this trend is likely to continue in the immediate future, the shift to these types of contracts may not survive in the long term. Precision medicine may make them obsolete.

Types of innovative biopharma contracts

The two most prevalent types... Talent, Data, and Tech: An Inclusive Approach to Drug Development

By GNS Healthcare | Drug Development, Clinical Trials, Artificial Intelligence

Interest in applying artificial intelligence and machine learning to healthcare has reached a pinnacle. Every day there are a slew of new articles and reports discussing the various ways that algorithms can transform the industry and there are many interesting technologies being developed and deployed—from digital health technologies that aim to make care delivery more patient-centric to machines that use image recognition to identify tumors before the human eye can see them.

A big area of potential growth for the use of AI is in precision medicine— the ability to customize the treatment... Optimizing Drug R&D: 3 Strategies to Embrace

By GNS Healthcare | Drug Discovery, Drug Development

Biopharma continues to look for ways to streamline the drug development process. With costs of bringing a drug to market now reaching $2.7 billion and the timeline stretching to nearly a decade, stakeholders across the healthcare continuum are clamoring for a faster, less expensive method.

The drug research and development process is well established and has remained largely unchanged over the past few decades and for good reason – it works. The methodology biopharma has followed has given the world many effective drugs which are both improving the quality of life for patient as well as... 3 Ways Machine Learning is Transforming Drug Development

By GNS Healthcare | Artificial Intelligence, Clinical Trials, Drug Development, Machine Learning

A recent study revealed that nearly half of all pipeline compounds and close to three quarters of oncology compounds are utilizing biomarker data during the drug development process. The same report indicated that investment in biomarker identification by biopharma has doubled over the past five years and is forecasted to increase over the next half decade. [1]

Biopharma’s increasing reliance on molecular data (most commonly genomic and proteomic) and the identification of specific biomarkers in the drug development process should not be surprising. Healthcare is transitioning to...


Subscribe to the GNS Blog





Tweets by @gnshealthcare
